Patients and Methods

Patients
Between 2007 and 2011, we studied 28 patients with unresectable ICC. From April 2010 through December 2011, 12 of these patients received TAI using a finepowder formulation of cisplatin (IA-call) plus oral S-1 (IA-call plus S-1 group). From April 2007 through March 2010, the other 16 patients (other treatment group) received various conventional treatments. Two patients were given radiation therapy, 1 received trans-arterial chemoembolization (TACE) with epirubicine, and 13 were treated with various regimens of chemotherapy. Six patients received intravenous gemcitabine (GEM, 1000mg/m 2 weekly), 1 received a combination of intravenous cisplatin, epirubicin, and 5-fluorouracil (5-FU), and 6 received TAI of IA-call (4 in combination with a daily 24-hour continuous intravenous infusion of 5-FU 1,000 mg/m 2 /day, and 2 without 5-FU). Since April 2010, we have changed our strategy in the treatment of unresectable ICC, and the IA-call plus oral S-1 therapy has been applied from this time. In this study, all the patients with unresectable ICC were divided into two groups at the time of changing the treatment strategy.
A d i a g n o s i s o f I C C w a s b a s e d o n e i t h e r histopathological or radiologic findings. All patients were deemed unresectable upon exploration due to the locally advanced, intrahepatic and bilateral dissemination, or distant metastases. All patients had good performance status (Eastern Cooperative Oncology Group (ECOG) performance status, 0-2), adequate liver function (bilirubin level < 2.0 mg/dL), adequate hematologic and bone marrow function (leukocyte count > 4,000/uL, platelet count > 100,000/μL), adequate renal function (creatinine level < 2.0 mg/dL), and measurable disease on computed tomography or magnetic resonance imaging. In addition, all patients could undergo angiography and selective visceral catheterization. Patients with biliary obstruction underwent endoscopic retrograde cholangiopancreatography-based or percutaneous transhepatic biliary drainage before administration of TAI and were required to have serum bilirubin levels of < 2.0 mg/dL. All the treatments were started soon after the definite diagnosis.
Treatment schedule
IA-call ® (cisplatin 100 mg/vial, 1.43 mg/mL; Nippon Kayaku Co., Ltd., Tokyo, Japan;) was dissolved in 70 mL of saline, heated to 50°C. A dose of 65 mg/m 2 cisplatin was then infused into the hepatic artery at a rate of 2 mL/min. on day 1 of each cycle. A catheter was placed in the femoral artery and introduced into the hepatic artery under angiographic guidance. After the procedure patients were observed overnight to manage pain and nausea, patients were routinely discharged home the following morning after evaluation of the results of laboratory studies.
S , 120 mg daily), divided into two doses. S-1 was given on days 1-28, every 42 days. This cycle was repeated if patients had recovered sufficiently from any drug-related toxicity. If patients had hematologic toxicity of grade 3 or higher or non-hematologic toxicity of grade 2 or higher, treatment was postponed until the toxicity subsided to grade 1 or lower.
Follow-up and toxicity assessment
After discharge, laboratory values were checked weekly on an outpatient basis. All patients underwent follow-up imaging studies 6 to 8 weeks after each TAI procedure. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (10) . In addition, serum carcinoembryonic antigen and CA19-9 levels were measured and included in the evaluation of therapeutic efficacy. Toxicity was evaluated using the National Cancer Institute Common Toxicity Criteria version 4.0.
Statistical analysis
Overall survival was calculated from the date of the first day of treatment to the date of death from any cause. Survival data were analysed using the KaplanMeier method. The statistical significance of differences between survival curves was determined with the logrank test. Univariate analysis was performed using chi-square tests. Multivariate analysis was performed with a Cox proportion-hazards model. Differences with p-values of < 0.05 were considered statistically significant. All analyses were performed using IBM SPSS Statistics 19 software (IBM SPSS, Tokyo, Japan).
Results
Twelve patients (median age 76 years [range: 61-83]) received a combination of hepatic arterial infusion of IA call plus oral S-1, and 16 (median age 67 years [57-79]) received conventional treatments (Table 1) . There was no significant difference between the two groups in the disease status, such as the number of tumor and the tumor size (Table 1) .
The median follow-up period for IA call plus S-1 and other treatment group were 10.1 (range 3.6-24.2 months) and 5.8 (range 1.5-24.2 months), respectively. A median of 4 cycles of IA-call plus S-1 (range, 2-9) were administered ( Table 2 ). All of the 12 patients in the IA-call plus S-1 group completed 2 or more courses of chemotherapy. Three patients underwent surgery and had recurrent disease. Intrahepatic recurrence occurred in all the patients, and 1 patient also had one patient (4.5%) had grade 3 anemia, and nonhematologic toxicity was generally mild, including nausea and vomiting. There was no treatment-related death. One patient was refused further chemotherapy because of toxicity (patient No. 1). All patients in the other treatment group died of tumor progression.
The overall survival was significantly longer in patients receiving TAI of IA-call plus S-1 (median multiple lung metastases. Eight patients are still alive, and 4 died of tumor progression 4.3 to 11.1months after initial treatment. No patient had a complete response (CR), 4 (33.3%) had partial responses (PR), 2 (16.6%) had stable disease (SD), and the other 6 (50%) had progressive disease (PD). All of the patients had decreased levels of the tumor marker CA-19-9.
About toxicity in these patients (Table 3) , only Figure 1 ; p < 0.01).
To determine the prognostic factors on survival in patients with unresectable ICC, univariate analyses were conducted (Table 4 ). The results of univariate analysis indicated that two variables, age and type of treatment, significantly affected the patients' overall survival (Table 4 ). Cox's proportional-hazard analysis including 3 variables (age, tumor size, and type of treatment) showed that only the type of treatment (IA call + S-1 vs. Other treatment, hazard ratio 3.97; 95% CI 1.28-12.3, p = 0.02) was an independent risk factor for overall survival.
Discussion
In this study, we evaluated the efficacy and toxicity of TAI using cisplatin plus oral S-1 in patients with unresectable ICC. Our results showed that overall survival was significantly longer in patients receiving TAI of IA-call plus S-1 (median survival time = 10.1; range, 3.6-23.2) than in those receiving other treatments (median survival time = 4.0; range; 0.3-24.2; p < 0.01). Moreover, IA-call plus S-1 was associated with moderate toxicity, with grade 3 anemia occurring in only 1 patient (4.5%).
Although systemic chemotherapy is indicated for unresectable ICC, conventional regimens are considered of limited effectiveness. There is an acute need for new treatment approaches. We used TAI of IA-call and S-1 to treat unresectable ICC for several reasons. ICC can extend in a multimodal and locoregional manner by means of infiltration of the parenchyma, the formation of intrahepatic satellite nodules, and vascular invasion (11) . The remnant liver is the most common site of recurrence (12, 13) . To prevent ICC from extending to the lymph nodes or other organs via vascular invasion, systemic chemotherapy might be useful. To date, the most promising approaches have used single-agent GEM. Median survival times of 14 months and 11 months have been obtained with combinations of GEM plus capecitabine (14) and GEM plus docetaxel (15), respectively. However, the therapeutic usefulness of these GEM-based combined regimens in patients with unresectable ICC has been limited by toxicity (16) . In contrast, recent phase 2 trials of S-1 monotherapy in patients with biliary tract cancer have obtained high response rates with mild toxicity (5, 6) . Therefore, we selected S-1 for systemic chemotherapy to prevent the spread of ICC to lymph nodes or other organs.
TAI allows the delivery of high doses of chemotherapeutic drugs directly to tumors, with minimal systemic drug exposure. Consequently, techniques for TAI-based chemotherapy have been developed to achieve higher therapeutic efficacy than that possible with intravenous administration of anticancer agents. With TAI, an anticancer agent is infused into an artery supplying the target tumor, thereby producing high drug concentrations at the target site in the liver. Because the blood supply of the biliary tree is derived from the hepatic artery, and ICC is usually confined to the liver, TAI might be a rational approach. To prevent the spread of ICC in the liver, TAI-based chemotherapy is considered promising (17) . Moreover, to obtain higher drug concentrations than those produced by conventional formations of cisplatin (0.5 mg/mL), we used IA-call (1.43 mg/mL), a finepowder formulation of cisplatin (9 reported that the administration of cisplatin through the hepatic artery provides a high drug concentration in the perfused blood, whereas the systemic concentration is much lower (20) . The few side effects with IA-call plus S-1 may thus be attributed by the lower systemic exposure to cisplatin. Combination chemotherapy with arterial IA-call plus oral S-1 might have a higher risk of some complications than conventional systemic chemotherapy. Angiography is generally a very safe procedure, and of the 12 patients, no complications related to the angiographic technique were observed. However, there is a small chance of minor or serious complications occurring, such as hemorrhage, arterial obstruction, and pseudoaneurysms (21) . To prevent these complications, we try to do the examination as patriotically as possible.
In conclusion, this pilot study suggests that TAI of IA-call plus S-1 is a safe and effective regimen. Our promising initial results warrant further phase II and III trials to confirm the feasibility and efficacy of IA-call plus S-1 in patients with unresectable ICC.
